PDGFRA and telomere syndrome: While no precise biomarker had been identified, these results suggested that the PDGF–PDGFRα axis plays an important role in the growth of human STS, and a phase III trial which randomized doxorubicin alone versus doxorubicin and olaratumab in advanced or metastatic STS has been conducted in 2016.